5Sμarrez F.Levitt MD.Adshead J.Barkin JS.Pancreatic supplements reduce symptomatic response of healthy subjects to a high fat meal.Dig Dis Sci,1999;4:1317-1321.
7Saito YA, Schoenfeld, Locke GRI 3rd. The epidemiology of irritable bowel syndrome in North America: a systemic review. Am J Gastroenterol, 2002, 97 : 1910-1915.
8Xiong LS, Chen MH, Chen HX, et al. A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling. Aliment Pharmarcol Ther, 2004, 19 : 1217-1224.
9Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology, 2002, 123: 2108-2131.
10Devaux M. Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. Gut, 2002, 51(Suppl 1): i67-i71.
6Okamtot S, Nakano K, Kosahra K, et al. Effects of pravasta- tin and UDCA on cholesterol and bile acid metabolism in patients with cholesterol gall-stones[J].J Gastroenterol, 1994,29(1) :47-55.
7Saunders KD,Catesa JA, Abedn MZ, Lovastatin and gallstone dissolution: a preliminary study[J]. Surgery, 1993,113 ( 1 ) : 28-35.
8Kuhnelt P, Mundlos S, Adler G. The size of enteric-coated mierospheres influences the intraduodenal lipolytic activity [J]. Z Gastroenterol, 1991,29(9) :417-421.
9Suarrez F, Levitt MD, Adshead J, et al. Pancreatic supple- ments reduce symptomatic response of healthy subjects to a high fat meal[J]. Dig Dis Sci, 1999,44(7):1317-1321.
